Endocan: A novel circulating proteoglycan

Indian Journal of Pharmacology

Volumn 46, Issue 6, 2014, Pages 579-583

  Kali, Arunava ^a   Rathan Shetty, K S ^a  

^a MAHATMA GANDHI MEDICAL COLLEGE AND RESEARCH INSTITUTE   (India)

Author keywords

Cancer; endocan; endothelial cell specific molecule; proteoglycan

Indexed keywords

CATHEPSIN G; ENDOCAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEOGLYCAN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; ESM1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANGIOGENESIS; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER PROGNOSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; OVARY CANCER; PROSTATE CANCER; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; SEPSIS; TUMOR GROWTH; TUMOR INVASION; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS;

ANIMALS; BIOMARKERS, TUMOR; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTEOGLYCANS; SEPSIS;

EID: 84916224387     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.144891     Document Type: Review

References (42)

1. Delehedde M, Devenyns L, Maurage CA, Vivès RR. Endocan in cancers: A lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol 2013; 2013: 705027
2. Sarrazin S, Lyon M, Deakin JA, Guerrini M, Lassalle P, Delehedde M, et al. Characterization and binding activity of the chondroitin/dermatan sulfate chain from Endocan, a soluble endothelial proteoglycan. Glycobiology 2010; 20: 1380-8
3. Sarrazin S, Maurage CA, Delmas D, Lassalle P, Delehedde M. Endocan as a biomarker of endothelial dysfunction in cancer. J Cancer Sci Ther 2010; 2: 47-52
4. Abid MR, Yi X, Yano K, Shih SC, Aird WC. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 2006; 72: 136-45
5. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al. ESM-1 is a novel human endothelial cell-specifi c molecule expressed in lung and regulated by cytokines. J Biol Chem 1996; 271: 20458-64
6. Tsai JC, Zhang J, Minami T, Voland C, Zhao S, Yi X, et al. Cloning and characterization of the human lung endothelial-cell-specifi c molecule-1 promoter. J Vasc Res 2002; 39: 148-59
7. Aitkenhead M, Wang SJ, Nakatsu MN, Mestas J, Heard C, Hughes CC. Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: Induction of ESM-1, (beta) ig-h3, and NrCAM. Microvasc Res 2002; 63: 159-71
8. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006; 34: 532-7
9. Abbas AK, Lichtman AH. Basic Immunology: Functions and Disorders of the Immune System. Philadelphia: Saunders/Elsevier; 2010
10. Béchard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, et al. Human endothelial-cell specifi c molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001; 167: 3099-106
11. Balta I, Balta S, Koryurek OM, Demirkol S, Mikhailidis DP, Celik T, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol 2014; 70: 291-6
12. Del Toro R, Prahst C, Mathivet T, Siegfried G, Kaminker JS, Larrivee B, et al. Identifi cation and functional analysis of endothelial tip cell-enriched genes. Blood 2010; 116: 4025-33
13. Maurage CA, Adam E, Minéo JF, Sarrazin S, Debunne M, Siminski RM, et al. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol 2009; 68: 633-41
14. Carrillo LM, Arciniegas E, Rojas H, Ramírez R. Immunolocalization of endocan during the endothelial-mesenchymal transition process. Eur J Histochem 2011; 55: e13
15. Recchia FM, Xu L, Penn JS, Boone B, Dexheimer PJ. Identifi cation of genes and pathways involved in retinal neovascularization by microarray analysis of two animal models of retinal angiogenesis. Invest Ophthalmol Vis Sci 2010; 51: 1098-105
16. Zuo L, Zhang SM, Hu RL, Zhu HQ, Zhou Q, Gui SY, et al. Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol 2008; 14: 4562-8
17. Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, et al. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 2013; 73: 1097-106
18. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al. Endocan or endothelial cell specifi c molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006; 1765: 25-37
19. Béchard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, et al. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem 2001; 276: 48341-9
20. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, et al. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 2007; 313: 1285-94
21. Mellberg S, Dimberg A, Bahram F, Hayashi M, Rennel E, Ameur A, et al. Transcriptional profi ling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis. FASEB J 2009; 23: 1490-502
22. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-In control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-71
23. Shin JW, Huggenberger R, Detmar M. Transcriptional profi ling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specifi c molecule-1 as a novel mediator of lymphangiogenesis. Blood 2008; 112: 2318-26
24. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009; 69: 836-44
25. Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifi es CXCR4 as a mediator of tip cell morphology and branching. Blood 2010; 115: 5102-10
26. Frahm KA, Nash CP, Tobet SA. Endocan immunoreactivity in the mouse brain: Method for identifying nonfunctional blood vessels. J Immunol Methods 2013; 398-399: 27-32
27. Yokota J. Tumor progression and metastasis. Carcinogenesis 2000; 21: 497-503
28. Scherpereel A, Gentina T, Grigoriu B, Sénéchal S, Janin A, Tsicopoulos A, et al. Overexpression of endocan induces tumor formation. Cancer Res 2003; 63: 6084-9
29. Kang YH, Ji NY, Lee CI, Lee HG, Kim JW, Yeom YI, et al. ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids 2011; 40: 1003-13
30. Satchi-Fainaro R, Ferber S, Segal E, Ma L, Dixit N, Ijaz A, et al. Prospective identifi cation of glioblastoma cells generating dormant tumors. PLoS One 2012; 7: e44395
31. Bissell MJ. Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? Am J Pathol 1999; 155: 675-9
32. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol 1999; 155: 739-52
33. El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, et al. A new alternative mechanism in glioblastoma vascularization: Tubular vasculogenic mimicry. Brain 2010; 133: 973-82
34. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006; 12: 4575-82
35. Yu PH, Chou SF, Chen CL, Hung H, Lai CY, Yang PM, et al. Upregulation of endocan by Epstein-Barr virus latent membrane protein 1 and its clinical signifi cance in nasopharyngeal carcinoma. PLoS One 2013; 8: e82254
36. Huang GW, Tao YM, Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 2009; 54: 389-94
37. El Behery MM, Seksaka MA, Ibrahiem MA, Saleh HS, El Alfy Y. Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstet 2013; 288: 1371-6
38. De Freitas Caires N, Legendre B, Parmentier E, Scherpereel A, Tsicopoulos A, Mathieu D, et al. Identifi cation of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal 2013; 78-79: 45-51
39. Kao SJ, Chuang CY, Tang CH, Lin CH, Bien MY, Yu MC, et al. Plasma endothelial cell-specific molecule-1 (ESM-1) in management of community-Acquired pneumonia. Clin Chem Lab Med 2014; 52: 445-51
40. Mikkelsen ME, Shah CV, Scherpereel A, Lanken PN, Lassalle P, Bellamy SL, et al. Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care 2012; 27: 522.e11-7
41. Güzel A, Duran L, Köksal N, Torun AC, Alaçam H, Ekiz BC, et al. Evaluation of serum endothelial cell specifi c molecule-1 (endocan) levels as a biomarker in patients with pulmonary thromboembolism. Blood Coagul Fibrinolysis 2014; 25: 272-6
42. Lunginnov Innovative Solutions to Access Endothelial Dysfunctions. Available from: http://www.lunginnov.com/index.php?/en/[Last accessed on 2014 May 02].